Document is current
Any future updates will be listed below
-
Authors
Salosensaari, Aaro https://orcid.org/0000-0001-6698-6093
Laitinen, Ville https://orcid.org/0000-0002-2653-1673
Havulinna, Aki S. https://orcid.org/0000-0002-4787-8959
Meric, Guillaume https://orcid.org/0000-0001-6288-9958
Cheng, Susan https://orcid.org/0000-0002-4977-036X
Perola, Markus
Valsta, Liisa
Alfthan, Georg
Inouye, Michael
Watrous, Jeramie D.
Long, Tao
Salido, Rodolfo A.
Sanders, Karenina
Brennan, Caitriona
Humphrey, Gregory C.
Sanders, Jon G. https://orcid.org/0000-0001-6077-4014
Jain, Mohit
Jousilahti, Pekka
Salomaa, Veikko https://orcid.org/0000-0001-7563-5324
Knight, Rob https://orcid.org/0000-0002-0975-9019
Lahti, Leo https://orcid.org/0000-0001-5537-637X
Niiranen, Teemu
-
Funding
Funding for this research was provided by:
Emil Aaltosen Säätiö (321351)
Academy of Finland
Suomen Lääketieteen Säätiö
Paavo Nurmen Säätiö
- License Information
-
More Information
Article History
Received: 17 July 2020
Accepted: 6 April 2021
First Online: 11 May 2021
Competing interests
: The authors declare the following competing interests: V.S. has consulted for Novo Nordisk and Sanofi and received honoraria from these companies. He also has ongoing research collaboration with Bayer AG, all unrelated to this study. The other authors declare no competing interests.
